OBJECTIVE: The aim of this study was to determine the time course over whic
h patients with primary sclerosing cholangitis (PSC) progress through the h
istological stages of the disease.
METHODS: One hundred seven patients with PSC who had at least two liver bio
psies were identified. The stage information from two consecutive biopsies
formed one observation and a continuous time Markov model was used to descr
ibe the rate of progression between biopsies.
RESULTS: Three hundred seven liver biopsies were performed in the 107 patie
nts giving a total of 200 observations. At 1 yr, 42% of patients in stage I
I disease progress, 66% at 2 vr, and 93% at 5 yr; whereas 14% of patients i
n stage III progress at 1 yr, 25% at 2 yr, and 52% at 5 yr. The frequency o
f progression of stage I disease could not be determined because of the sma
ll number of patients in stage I. Regression of histological stage was obse
rved in 30 of 200 total observations (15%), and in 30 of 85 observations (3
5%) in which there was a change in stage.
CONCLUSIONS: These data regarding histological progression in PSC may be po
tentially helpful in determining the number of patients and length of time
necessary to appreciate a treatment effect in clinical trials. However, the
high degree of sampling variability in PSC may restrict the usefulness of
serial liver biopsies as a means of evaluating treatment efficacy. (C) 1999
by Am. Cell. of Gastroenterology.